TABLE 4.
Positive and negative predicted values of the rapid test according to the reported prevalence of the CzIE in bloodstream MSSA from Latin America and the United States
| Country | % Prevalencea | Sensitivityb | Specificityb | PPVc | NPVc | Source |
|---|---|---|---|---|---|---|
| Argentina | 55 | 88.9 | 91.9 | 92.8 | 87.6 | (13) |
| Brazil | 32 | 60.9 | 80.8 | 59.8 | 81.4 | (23) |
| Colombia | 39d | 84.9 | 91.2 | 86.0 | 90.4 | (22, 23) |
| Chile | 32 | 91.2 | 83.1 | 70.1 | 92.0 | (23) |
| Ecuador | 41d | 80.8 | 92.1 | 87.7 | 87.3 | (22, 23) |
| Guatemala | 44 | 82.6 | 84.4 | 80.6 | 86.1 | (23) |
| Perú | 32d | 90.9 | 92.1 | 84.4 | 95.6 | (22, 23) |
| Venezuela | 30.5d | 60 | 100 | 100 | 85.1 | (22, 23) |
| United States | 25 | 80.0 | 93.2 | 79.6 | 93.3 | (21)e |
| 4 | 80.0 | 93.2 | 32.8 | 99.1 | (19) | |
| 10 | 80.0 | 93.2 | 56.6 | 97.7 | This study |
a
Prevalence of the CzIE in MSSA isolates recovered from bloodstream infections in each country, as reported previously. Only prevalences based on cefazolin MIC ≥ 16 μg/ml at high inoculum were included.
b
Sensitivity and specificity of the rapid test calculated in this study.
c
Positive predictive values (PPV) and negative predictive values (NPV) were calculated taking into consideration previous reported prevalences.
d
The value represents prevalence mean of two reported studies.
e
The prevalence of CzIE in this study correspond to isolates recovered from 24 hemodialysis patients.